Islet amyloid polypeptide and type 2 diabetes

Experimental Gerontology

Volumn 38, Issue 4, 2003, Pages 347-351

  Marzban, Lucy ^a   Park, Kirily ^a   Verchere, C Bruce ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Amylin; Amyloid; Beta cells; Diabetes; Islet amyloid polypeptide

Indexed keywords

AMYLIN; AMYLOID;

CORRELATION ANALYSIS; CYTOTOXICITY; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS INSUFFICIENCY; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY;

EID: 0037379714     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0531-5565(03)00004-4     Document Type: Short Survey

References (34)

1. Anguiano M., Nowak R.J., Lansbury P.T. Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry. 41:2002;11338-11343.
2. Clark A., Wells C.A., Buley I.D., Cruickshank J.K., Vanhegan R.I., Matthews D.R., Cooper G.J.S., Holman R.R., Turner R.C. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. 9:1988;151-159.
3. Cooper G.J.S., Willis A.C., Clark A., Turner R.C., Sim R.B., Reid K.B.M. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl Acad. Sci. USA. 84:1987;8628-8632.
4. Furukawa H., Carroll R.J., Swift H.H., Steiner D.F. Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic beta-cell line MIN6. Diabetes. 48:1999;1395-1401.
5. Gebre-Medhin S., Mulder H., Pekny M., Westermark G., Törnell J., Westermark P., Sundler F., Ahren B., Betsholtz C. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem. Biophys. Res. Commun. 250:1998;271-277.
6. Gebre-Medhin S., Olofsson C., Mulder H. Islet amyloid polypeptide in the islets of Langerhans: friend or foe? Diabetologia. 43:2000;687-695.
7. Hiddinga H.J., Eberhardt N.L. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. Am. J. Pathol. 154:1999;1077-1088.
8. Höppener J.W.M., Oosterwijk C., Nieuwenhuis M.G., Posthuma G., Thijssen J.H.H., Vroom T.M., Ahren B., Lips C.J.M. Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia. 42:1999;427-434.
9. Hou X., Ling Z., Quartier E., Foriers A., Schuit F., Pipeleers D., Van Schravendijk C. Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Diabetologia. 42:1999;188-194.
10. Jaikaran E.T., Higham C.E., Serpell L.C., Zurdo J., Gross M., Clark A., Fraser P.E. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 308:2001;515-525.
11. Kahn S.E., D'Alessio D.A., Schwartz M.W., Fujimoto W.Y., Ensinck J.W., Taborsky G.J. Jr., Porte D. Jr. Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes. 39:1990;634-638.
12. Kahn S.E., Verchere C.B., Andrikopoulos S., Asberry P.J., Leonetti D.L., Wahl P.W., Boyko E.J., Schwartz R.S., Newell-Morris L., Fujimoto W.Y. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes. 47:1998;640-645.
13. Kahn S.E., Andrikopoulos S., Verchere C.B. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes. 48:1999;241-253.
14. de Koning E.J.P., Bodkin N.L., Hansen B.C., Clark A. Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia. 36:1993;378-384.
15. de Koning E.J.P., Morris E.R., Hofhuis F.M.A., Posthuma G., Hoppener J.W.M., Morris J.F., Capel P.J.A., Clark A., Verbeek J.S. Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc. Natl Acad. Sci. USA. 91:1994;8467-8471.
16. Lorenzo A., Razzaboni B., Weir G.C., Yankner B.A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature. 368:1994;756-760.
17. Mirzabekov T.A., Lin M.C., Kagan B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271:1996;1988-1992.
18. Nilsson M.R., Raleigh D.P. Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. J. Mol. Biol. 294:1999;1375-1385.
19. Nishi M., Bell G.I., Steiner D.F. Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 33:1990;628-630.
20. Park K., Verchere C.B. Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. Implications for islet amyloid formation. J. Biol. Chem. 276:2001;16611-16616.
21. Porte D. Jr., Kahn S.E. Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction? Diabetes. 38:1989;1333-1336.
22. Sakagashira S., Sanke T., Hanabusa T., Shimomura H., Ohagi S., Kumagaye K.Y., Nakajima K., Nanjo K. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes. 45:1996;1279-1281.
23. Sexton P.M., Paxinos G., Kenney M.A., Wookey P.J., Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience. 62:1994;553-567.
24. Soeller W.C., Janson J., Hart S.E., Parker J.C., Carty M.D., Stevenson R.W., Kreutter D.K., Butler P.C. Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. Diabetes. 47:1998;743-750.
25. Turner R., Cull C., Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 124:1996;136-145.
26. Verchere C.B., D'Alessio D.A., Palmiter R.D., Weir G.C., Bonner-Weir S., Baskin D.G., Kahn S.E. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc. Natl Acad. Sci. USA. 93:1996;3492-3496.
27. 2-terminal cleavage site. Diabetes. 50:2001;534-539.
28. Westermark P. Amyloid and polypeptide hormones: what is their interrelationship? Amyloid. 1:1994;47-58.
29. Westermark P., Wernstedt C., Wilander E., Hayden D.W., O'Brien T.D., Johnson K.H. Amyloid fibrils in human insulinoma and islets of langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets. Proc. Natl Acad. Sci. USA. 84:1987;3881-3885.
30. Westermark P., Engström U., Westermark G.T., Johnson K.H., Permerth J., Betsholtz C. Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diabetes Res. Clin. Pract. 7:1989;219-226.
31. Westermark P., Engström U., Johnson K.H., Westermark G.T., Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl Acad. Sci. USA. 87:1990;5036-5040.
32. Westermark P., Eizirik D.L., Pipeleers D.G., Hellerstrom C., Andersson A. Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia. 38:1995;543-549.
33. Young A. Amylin's physiology and its role in diabetes. Curr. Opin. Endocrinol. Diabetes. 4:1997;282-290.
34. Zumpe E.T., Tilakaratne N., Fraser N.J., Christopoulos G., Foord S.M., Sexton P.M. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem. Biophys. Res. Commun. 267:2000;368-372.